Real-life experience after 3 months with tezepelumab before marketing approval
CONCLUSIONS: In this preliminary real-world experience prior to the official approval of tezepelumab in Spain, this monoclonal antibody showed promising results and suggests its potential as a valuable alternative for the treatment of severe asthma.PMID:38459894 | DOI:10.15586/aei.v52i2.1063 (Source: Allergologia et Immunopathologia)
Source: Allergologia et Immunopathologia - March 9, 2024 Category: Allergy & Immunology Authors: Victoria Villalobos Viol án Beatriz Gonz ález Cano Miguel Ángel Racionero Casero Elo ína González-Mancebo Esther Mohedano Vicente Mar ía Jesús Trujillo Trujillo Mar Gandolfo-Cano Source Type: research
Real-life experience after 3 months with tezepelumab before marketing approval
CONCLUSIONS: In this preliminary real-world experience prior to the official approval of tezepelumab in Spain, this monoclonal antibody showed promising results and suggests its potential as a valuable alternative for the treatment of severe asthma.PMID:38459894 | DOI:10.15586/aei.v52i2.1063 (Source: Allergologia et Immunopathologia)
Source: Allergologia et Immunopathologia - March 9, 2024 Category: Allergy & Immunology Authors: Victoria Villalobos Viol án Beatriz Gonz ález Cano Miguel Ángel Racionero Casero Elo ína González-Mancebo Esther Mohedano Vicente Mar ía Jesús Trujillo Trujillo Mar Gandolfo-Cano Source Type: research
A Global Phase II Randomized trial comparing Oral Taxane ModraDoc006/r to Intravenous Docetaxel in Metastatic Castration Resistant Prostate Cancer
ModraDoc006, an oral formulation of docetaxel, is co-administered with the cytochrome P450-3A4 and P-glycoprotein inhibitor, ritonavir (r): ModraDoc006/r. The preliminary efficacy and safety of oral ModraDoc006/r was evaluated in a global randomized phase II trial and compared to the current standard chemotherapy regimen of intravenous (i.v.) docetaxel and prednisone. (Source: European Journal of Cancer)
Source: European Journal of Cancer - March 9, 2024 Category: Cancer & Oncology Authors: Ulka N. Vaishampayan, Marianne Keessen, Robert Dreicer, Elisabeth I. Heath, Tomas Buchler, P éter F. Árkosy, CsosziTibor Csöszi, Pawel Wiechno, Evgeny Kopyltsov, Sergey V. Orlov, Alexey Plekhanov, Maria Smagina, Sergei Varlamov, Neal D. Shore Tags: Original Research Source Type: research
A single ‐centre, real‐world study of BTK inhibitors for the initial treatment of MYD88mut/CD79Bmut diffuse large B‐cell lymphoma
ConclusionThis study suggests that newly diagnosed DLBCL patients with MYD88mut and/or CD79Bmut may benefit from BTKis according to real-world clinical data. (Source: Cancer Medicine)
Source: Cancer Medicine - March 8, 2024 Category: Cancer & Oncology Authors: Ting Deng,
Shiyuan Zhang,
Min Xiao,
Jia Gu,
Liang Huang,
Xiaoxi Zhou Tags: RESEARCH ARTICLE Source Type: research
A single-centre, real-world study of BTK inhibitors for the initial treatment of MYD88 < sup > mut < /sup > /CD79B < sup > mut < /sup > diffuse large B-cell lymphoma
CONCLUSION: This study suggests that newly diagnosed DLBCL patients with MYD88mut and/or CD79Bmut may benefit from BTKis according to real-world clinical data.PMID:38457222 | DOI:10.1002/cam4.7005 (Source: Cancer Control)
Source: Cancer Control - March 8, 2024 Category: Cancer & Oncology Authors: Ting Deng Shiyuan Zhang Min Xiao Jia Gu Liang Huang Xiaoxi Zhou Source Type: research
